MEDIOCON INC – Kynostatin, also known as KNI-272 and NSC 651714, is a synthetic peptidomimetic compound developed as a highly potent and selective HIV protease inhibitor. It contains an allophenylnorstatine-derived transition-state-mimicking structure and has been investigated in preclinical antiviral research.
Kynostatin (KNI-272) is a conformationally constrained tripeptide-derived HIV protease inhibitor. Research published on KNI-272 describes it as a highly selective inhibitor of HIV protease and reports antiviral activity against HIV-1 and HIV-2 in experimental models.
The compound was designed using allophenylnorstatine (Apns) as a transition-state mimic, allowing interaction with the catalytic region of HIV protease.
Product Name: Kynostatin
Development Code: KNI-272
NSC Number: NSC 651714
CAS Number: 147318-81-8
Molecular Formula: C₃₃H₄₁N₅O₆S₂
Molecular Weight: 667.80 g/mol
Chemical Class: Peptidomimetic / Protease Inhibitor
Therapeutic Research Class: HIV Protease Inhibitor
PubChem CID: 3839
InChIKey: NJBBLOIWMSYVCQ-UHFFFAOYSA-N
PubChem reports the molecular formula C₃₃H₄₁N₅O₆S₂ and molecular weight 667.8 g/mol for Kynostatin/KNI-272. NCATS lists CAS 147318-81-8 for KNI-272.
Kynostatin is designed to inhibit HIV protease, an essential viral enzyme involved in processing viral polyproteins into mature viral proteins.
KNI-272 incorporates an allophenylnorstatine-based transition-state mimic. Experimental studies reported highly potent inhibition of HIV protease, including a reported Ki of 0.0055 nM in one research study.
MEDIOCON INC focuses on supplying pharmaceutical and specialty research compounds with emphasis on quality, consistency, technical documentation and reliable supply.
For Kynostatin, quality evaluation may include:
The exact analytical acceptance criteria should be established according to the applicable research specification and batch-specific Certificate of Analysis.
Kynostatin has been investigated primarily in:
Early research identified KNI-272 as a potent antiviral research compound, while subsequent studies characterized its interaction with HIV protease.
Kynostatin has been structurally characterized as a crystalline compound, including a hydrate form in crystallographic research.
Appearance: Not reliably available / Cannot be verified
For your website, it is safer not to invent a white/off-white powder specification unless your actual supplier or batch COA confirms it.
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), analytical data and technical specifications should be confirmed with MEDIOCON INC according to the intended research application.
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Kynostatin API Manufacturer and Supplier in India (CAS 147318-81-8) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Kynostatin API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance